TABLE 1.

Characterization of immunodominant domains within the RSV-A2 fusion protein^a

Donor HLA type or pool	Peptides in pool	No. of spots/106 PBMC
		CE-7	CE-4	CE-3	VB-5	VB-2	VP-1	CH-1
HLA-A		3, 28	2	2	2	1, 29	2	2
HLA-B		7, 35	8, 18	40	35, 62	44, 57	44	27, 6
HLA-C			7		4		5	2, 3
HLA-DR		DRB1*01	DRB1*01	DRB1*0401	DRB1*0401	DRB1*0701	DRB1*1302	DRB1*15
			DRB1*03	DRB1*03	DRB1*0403	DRB1*1101	DRB1*15	DRB1*16
HLA-DQ		DQB1*05	DQB1*02	DQB1*02	DQB1*03	DQB1*03	DQB1*06	DQB1*0502
			DQB1*05	DQB1*03				DQB1*0602
Untreated		4	12	4	46	10	14	32
RSV		92b	66	108	>350	162	156	>250
Pool 1	1-6	22	12	42	240	34	94	42
Pool 2	7-10, 13, 14	6	12	40	220	38	36	68
Pool 3	15-20	10	12	28	152	38	12	48
Pool 4	21-26	0	4	0	62	18	10	20
Pool 5	27-32	12	12	12	100	48	22	50
Pool 6	33-38	4	16	24	114	28	26	66
Pool 7	39-44	20	32	26	98	100	32	28
Pool 8	45-50	28	22	26	142	28	140	38
Pool 9	51-56	28	24	24	176	26	88	26
Pool 10	57-62	8	24	40	106	40	42	28
Pool 11	63-68	10	12	18	150	12	12	28
Pool 12	71-76	8	14	14	176	28	24	26
Pool 13	77-82	18	10	14	165	18	46	138
Pool 14	83, 84, 86-88, 90	10	14	36	144	24	34	78
Pool 15	69, 70, 91-94	4	4	8	42	84	26	72

^aPools of six consecutive peptides (20 μM) were tested in a direct 24-h Elispot assay (triplicate) with PBMC from healthy adult blood donors. No. of spots per 10⁶ PBMC are depicted.

^bThe number of background spots (no peptide) was not subtracted.